These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 1899793)

  • 1. Plasma levels of tissue-type plasminogen activator and von Willebrand factor in patients with Raynaud's phenomenon.
    Marasini B; Cugno M; Agostoni A
    Arthritis Rheum; 1991 Feb; 34(2):255-6. PubMed ID: 1899793
    [No Abstract]   [Full Text] [Related]  

  • 2. Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis.
    Herrick AL; Illingworth K; Blann A; Hay CR; Hollis S; Jayson MI
    Ann Rheum Dis; 1996 Feb; 55(2):122-7. PubMed ID: 8712862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue-type plasminogen activator and von Willebrand factor plasma levels as markers of endothelial involvement in patients with Raynaud's phenomenon.
    Marasini B; Cugno M; Bassani C; Stanzani M; Bottasso B; Agostoni A
    Int J Microcirc Clin Exp; 1992 Nov; 11(4):375-82. PubMed ID: 1459797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of early endothelial damage in patients with Raynaud's phenomenon.
    Gualtierotti R; Ingegnoli F; Griffini S; Grovetti E; Borghi MO; Bucciarelli P; Meroni PL; Cugno M
    Microvasc Res; 2017 Sep; 113():22-28. PubMed ID: 28450106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The effect of beraprost sodium on the Raynaud's phenomenon].
    Hiida M; Ushiyama O; Suzuki N; Ohta A; Nagasawa K; Yamaguchi M
    Nihon Rinsho Meneki Gakkai Kaishi; 1996 Jun; 19(3):193-200. PubMed ID: 8810544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon.
    Kahaleh MB; Osborn I; LeRoy EC
    Ann Intern Med; 1981 Apr; 94(4 pt 1):482-4. PubMed ID: 6782927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. von Willebrand factor activity in primary and in scleroderma-associated Raynaud's phenomenon.
    Cuenca R; Fernadez-Cortijo J; Fonollosa V; Lima J; Simeon CP; Vilardell M; Pico M
    Lancet; 1990 May; 335(8697):1095. PubMed ID: 1970389
    [No Abstract]   [Full Text] [Related]  

  • 8. Measurement of soluble adhesion molecules in primary Raynaud's phenomenon and in Raynaud's phenomenon secondary to connective tissue diseases.
    Brevetti G; De Caterina M; Martone VD; Corrado S; Silvestro A; Spadaro G; Scopacasa F
    Int J Clin Lab Res; 2000; 30(2):75-81. PubMed ID: 11043500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline plasma fibrinolysis and its correlation with clinical manifestations in patients with Raynaud's phenomenon.
    Lau CS; McLaren M; Mackay I; Belch JJ
    Ann Rheum Dis; 1993 Jun; 52(6):443-8. PubMed ID: 8323396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of total-body cold exposure on plasma concentrations of von Willebrand factor, endothelin-1 and thrombomodulin in systemic lupus erythematosus patients with or without Raynaud's phenomenon.
    Matsuda J; Tsukamoto M; Gohchi K; Saitoh N; Miyajima Y; Kazama M
    Acta Haematol; 1992; 88(4):189-93. PubMed ID: 1337960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma levels of tumor necrosis factor and endothelial response in patients with chronic arterial obstructive disease or Raynaud's phenomenon.
    Cimminiello C; Arpaia G; Toschi V; Rossi F; Aloisio M; Motta A; Bonfardeci G
    Angiology; 1994 Dec; 45(12):1015-22. PubMed ID: 7985828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Endothelin-1 in pathogenesis of Raynaud's syndrome].
    Knapik-Kordecka M; Adamiec R; Ciosek W
    Pol Merkur Lekarski; 2001 Jun; 10(60):424-5. PubMed ID: 11503255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The associations between plasma levels of von Willebrand factor and fibrinogen with Raynaud's phenomenon in men and women.
    Fraenkel L; Tofler GH; Zhang Y; Silbershatz H; D'Agostino RB; Wilson PW; Felson DT
    Am J Med; 2000 May; 108(7):583-6. PubMed ID: 10806290
    [No Abstract]   [Full Text] [Related]  

  • 14. Association of von Willebrand factor and fibrinogen plasma levels with primary Raynaud's phenomenon in male and female patients.
    Takáts AT; Shemirani AH; Zsóri KS; András C; Csiki Z
    Rheumatol Int; 2013 Apr; 33(4):1083-4. PubMed ID: 22108676
    [No Abstract]   [Full Text] [Related]  

  • 15. Endothelin, vasoconstriction, and endothelial damage in Raynaud's phenomenon.
    Cimminiello C; Milani M; Uberti T; Arpaia G; Perolini S; Bonfardeci G
    Lancet; 1991 Jan; 337(8733):114-5. PubMed ID: 1670699
    [No Abstract]   [Full Text] [Related]  

  • 16. von Willebrand factor antigen, tissue-type plasminogen activator antigen, and risk of death in human immunodeficiency virus 1-related clinical disease: independent prognostic relevance of tissue-type plasminogen activator.
    Schved JF; Gris JC; Arnaud A; Martinez P; Sanchez N; Wautier JL; Sarlat C
    J Lab Clin Med; 1992 Sep; 120(3):411-9. PubMed ID: 1517688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [t-PA and PAI in patients with Raynaud's syndrome in treatment with a stable prostacyclin analog].
    Pola P; de Martini D; Gerardino L
    Angiologia; 1992; 44(2):62-6. PubMed ID: 1378247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of von Willebrand factor and tissue plasminogen activator concentrations in plasma and serum.
    Nilsson TK; Thögersen AM; Jansson JH; Boman K
    Clin Chem; 1996 Jun; 42(6 Pt 1):976-7. PubMed ID: 8665694
    [No Abstract]   [Full Text] [Related]  

  • 19. Persistent Raynaud's phenomenon after exposure to vinyl chloride monomer: assessment of endothelial damage.
    Fontana L; Marion MJ; Catilina P
    Clin Exp Rheumatol; 2004; 22(1):132-3. PubMed ID: 15005018
    [No Abstract]   [Full Text] [Related]  

  • 20. The role of endothelin-1 and selected cytokines in the pathogenesis of Raynaud's phenomenon associated with systemic connective tissue diseases.
    Rychlik-Golema W; Mastej K; Adamiec R
    Int Angiol; 2006 Jun; 25(2):221-7. PubMed ID: 16763543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.